• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aerpio Pharmaceuticals, Inc.

    9/2/21 4:30:32 PM ET
    $ARPO
    Major Pharmaceuticals
    Health Care
    Get the next $ARPO alert in real time by email
    SC 13G 1 ea146885-13gvivo_aadibio.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.   )*

     

    Aadi Bioscience, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    00032Q104
    (CUSIP Number)
     
    August 26, 2021
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00032Q104
    1 NAMES OF REPORTING PERSONS  
    Vivo Panda, LLC  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a)       ☒
    (b)       ☐
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    586,042 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    586,042 (1)
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    586,042 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    2.8% (2)
    12 TYPE OF REPORTING PERSON (See Instructions)
    OO

     

    (1)The shares of common stock, $0.0001 par value (“Common Stock”) of Aadi Bioscience, Inc. (the “Issuer”) are held of record by Vivo Panda, L.P. Vivo Panda, LLC is the general partner of Vivo Panda, L.P.
    (2)Based on 20,838,292 shares of Common Stock of the Issuer outstanding as of August 26, 2021, upon completion of the merger.

     

    2

     

     

    CUSIP No. 00032Q104
    1 NAMES OF REPORTING PERSONS  
    Vivo Opportunity, LLC  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a)       ☒
    (b)       ☐
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    841,171 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    841,171 (1)
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    841,171 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.0% (2)
    12 TYPE OF REPORTING PERSON  (See Instructions)
    OO

     

    (1)The shares of Common Stock of the Issuer are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.
    (2)Based on 20,838,292 shares of Common Stock of the Issuer outstanding as of August 26, 2021, upon completion of the merger.

     

    3

     

     

    Item 1.  (a)Name of Issuer:

     

    Aadi Biosciences, Inc.

     

    (b)Address of Issuer's Principal Executive Offices:

     

    17383 Sunset Blvd, Suite A250

     

    Pacific Palisades, CA 90272

     

    Item 2. (a) Name of Person Filing:

     

    This Schedule 13G is filed jointly by Vivo Panda, LLC and Vivo Opportunity, LLC. Vivo Panda, LLC and Vivo Opportunity, LLC have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

    (c)Citizenship:

     

    Vivo Panda, LLC is a Delaware limited liability company

     

    Vivo Opportunity, LLC is a Delaware limited liability company

     

    (d)Title of Class of Securities:

     

    Common stock, $0.0001 par value

     

    (e)CUSIP Number:

     

    00032Q104

     

    Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act.
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act.
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act.
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940.
           
      (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    4

     

     

      (i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned:

     

    (1) Vivo Panda, LLC

     

    The 586,042 shares of Common Stock are held of record by Vivo Panda, L.P. Vivo Panda, LLC is the general partner of Vivo Panda, L.P. The voting members of Vivo Panda, LLC are Mahendra Shah, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

     

    (2) Vivo Opportunity, LLC

     

    The 841,171 shares of Common Stock are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Gaurav Aggarwal, Frank Kung, Hongbo Lu, Michael Chang, and Kevin Dai, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

     

    (b) Percent of class:

     

    Vivo Panda, LLC: 2.8%

     

    Vivo Opportunity, LLC: 4.0%

     

    (c) Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    Vivo Panda, LLC: 586,042 shares

     

    Vivo Opportunity, LLC: 841,171 shares

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    Vivo Panda, LLC: 586,042 shares

     

    Vivo Opportunity, LLC: 841,171 shares

     

    (iv)Shared power to dispose of or to direct the disposition of: 0

     

    5

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Vivo Panda, LLC
       
      September 2, 2021
      (Date)
       
      /s/ Mahendra Shah
      (Signature)
       
      Managing Member
      (Title)
       
      Vivo Opportunity, LLC
       
      September 2, 2021
      (Date)
       
      /s/ Gaurav Aggarwal
      (Signature)
       
      Managing Member
      (Title)

     

    7

     

     

    Exhibit 99.1

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock, $0.0001 par value, of Aadi Bioscience, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.

     

    Vivo Panda, LLC
       
      September 2, 2021
      (Date)
       
      /s/ Mahendra Shah
      (Signature)
       
      Managing Member
      (Title)
       
    Vivo Opportunity, LLC
       
      September 2, 2021
      (Date)
       
      /s/ Gaurav Aggarwal
      (Signature)
       
      Managing Member
      (Title)

     

     

     
    Get the next $ARPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARPO

    DatePrice TargetRatingAnalyst
    7/8/2021$22.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update

      Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary closing conditions CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update. Key Business Update: On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., a Delaware company ("Aadi"), and Aspen Merger Subsidiary, Inc., a D

      8/11/21 4:10:00 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting

      CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on develo

      6/4/21 9:15:00 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting

      CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) announced that Aadi Bioscience ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing its abstract to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compound

      5/19/21 7:52:31 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    SEC Filings

    See more
    • SEC Form EFFECT filed by Aerpio Pharmaceuticals, Inc.

      EFFECT - Aadi Bioscience, Inc. (0001422142) (Filer)

      10/4/21 12:15:39 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 filed by Aerpio Pharmaceuticals, Inc.

      S-8 - Aadi Bioscience, Inc. (0001422142) (Filer)

      9/24/21 4:58:29 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form S-3 filed by Aerpio Pharmaceuticals, Inc.

      S-3 - Aadi Bioscience, Inc. (0001422142) (Filer)

      9/24/21 4:53:34 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aerpio Pharmaceuticals upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Aerpio Pharmaceuticals from Neutral to Buy and set a new price target of $22.00

      7/8/21 6:10:14 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • HC Wainwright resumed coverage on Aerpio Pharmaceuticals

      HC Wainwright resumed coverage of Aerpio Pharmaceuticals with a rating of Hold

      3/15/21 7:37:51 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Delaney Brendan

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      9/22/21 4:13:20 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by new insider Delaney Brendan

      3 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      9/22/21 4:07:42 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Desai Neil

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      9/10/21 5:05:21 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial

      CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $47.3 million as of September 30, 2020. As part of this process, the Company will explore strategic options for partnering its programs, as well as, the potential for an acquisition, company sale, merger, business combination, asset sale, in-license, out-licens

      1/5/21 4:01:00 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Aerpio Pharmaceuticals, Inc.

      SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/8/21 5:30:33 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Aerpio Pharmaceuticals, Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/7/21 5:26:49 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D filed by Aerpio Pharmaceuticals, Inc.

      SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/7/21 5:25:38 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care